Last updated April 4, 2025
by Antoine Tardif, United.AI
Excerpt:
“What inspired the NAi Interrogative Biology® platform, and how does it differentiate BPGbio from other biopharma companies leveraging AI?
Since joining BPGbio, I’ve been continually impressed by the depth of innovation and long-term vision that went into building the NAi Interrogative Biology® platform. As someone who has spent two decades in biotechnology and business development—evaluating a wide range of platforms and companies—I can say that NAi stands out for its biology-first foundation and the depth of data it interrogates.
BPGbio was among the first to pioneer AI for drug discovery. Over the last 15 years, the team has refined NAi into a platform integrating proprietary multi-omics data and one of the world’s largest longitudinal biobanks. Unlike other companies that rely on narrow technologies or public datasets for a single disease discovery program, we integrate multiomics capabilities with our own proprietary biobank that houses hundreds of thousands of longitudinal, clinically annotated samples and use causal Bayesian AI, not generative AI modeling to uncover biologically-based insights, that can inform virtually any stage of drug discovery and increase the likelihood of clinical development success. We’re not just identifying targets; we’re using AI to design our clinical trials, understand the results of our clinical trials, and refine our treatment approaches.
Our results speak for themselves: We have one of the most advanced and robust clinical pipelines in the AI biotech industry. This pipeline includes two active phase 2 trials in aggressive cancers, multiple phase 3-ready programs, and over one hundred novel targets and biomarkers we’ve identified using our AI models.”
For the full interview, please visit the Unite.AI website: John Beeler, Ph.D., SVP of Business Development, BPGbio – Interview Series
About BPGbio
BPGbio is a leading biology-first AI-powered clinical stage biopharma focused on mitochondrial biology and protein homeostasis. The company has a deep pipeline of AI-developed therapeutics spanning oncology, rare disease and neurology, including several in late-stage clinical trials. BPGbio’s novel approach is underpinned by NAi, its proprietary Interrogative Biology Platform, protected by over 400 US and international patents; one of the world’s largest clinically annotated non-governmental biobanks with longitudinal samples; and exclusive access to the most powerful supercomputer in the world. With these tools, BPGbio is redefining how patient biology can be modeled using bespoke Bayesian AI specifically designed for solving large-scale biology challenges. Headquartered in greater Boston, the company is at the forefront of a new era in medicine, combining biology, multi-modal data, and AI to transform the way we understand, diagnose, and treat disease. For more information, visit www.bpgbio.com.
Contact
Media Contact:
media@bpgbio.com
